BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow
limitation and debilitating symptoms. For patients with moderate-to-severe COPD, long …

Rationale: Indacaterol is the first once-daily, long-acting inhaled β2-agonist bronchodilator
studied in patients with chronic obstructive pulmonary disease (COPD). Objectives: To …

Background Indacaterol is a long-acting inhaled β2-agonist (LABA) for the treatment of
chronic obstructive pulmonary disease (COPD). In previous studies, indacaterol provided 24 …

Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β2-agonist bronchodilator
recently approved in Europe for the treatment of chronic obstructive pulmonary disease …

Background Indacaterol is a novel, once-daily (od) inhaled, long-acting β 2-agonist in
development for chronic obstructive pulmonary disease (COPD). This 12-week, double-blind …

An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD)
management and improving adherence with prescribed therapy is to reduce the dose …

The important role of ligand–receptor binding kinetics in drug design and discovery is
increasingly recognized by the drug research community. Over the past decade …

BACKGROUND: The drug development process can be streamlined by combining the
traditionally separate stages of dose-finding (Phase IIb) and confirmation of efficacy and …

Indacaterol is a novel β2-adrenoceptor agonist in development for the once-daily treatment
of asthma and chronic obstructive pulmonary disease. The present study evaluated the …